On this page

sulfacetamide sodium

Prescription ANDA TE AT Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Sulfacetamide Sodium
Generic name
sulfacetamide sodium
Dosage form
Solution/ Drops
Route
Ophthalmic
Marketing category
ANDA · ANDA
Labeler
Bausch & Lomb Incorporated
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
6
Packages
6
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Sulfacetamide Sodium 100 mg/mL 832864 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Solution/ Drops
Route of administration
Ophthalmic
Presentations
12

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Sulfonamide Antibacterial [EPC] EPC 6 members — no class page
Sulfonamides [CS] CS All 18 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
040066
Application type
ANDA · Abbreviated New Drug Application
Approval date
December 28, 1994
Sponsor
BAUSCH AND LOMB
Products on application
1
Submissions recorded
13
Products approved under application 040066.
Product Trade name Form Strength Ingredient Status TE Flags
040066-001 SULFACETAMIDE SODIUM SOLUTION/DROPS SULFACETAMIDE SODIUM Prescription AT RS

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
No
Reference Standard
Yes

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 040066.
Type No. Action Status Date Review
Supplement 12 Manufacturing (CMC) Approved November 27, 2001 —
Supplement 11 Manufacturing (CMC) Approved March 7, 2001 —
Supplement 10 Manufacturing (CMC) Approved October 5, 2000 —
Supplement 9 Manufacturing (CMC) Approved June 27, 2000 —
Supplement 6 Manufacturing (CMC) Approved May 18, 2000 —
Supplement 8 Manufacturing (CMC) Approved May 15, 2000 —
Supplement 7 Manufacturing (CMC) Approved April 28, 2000 —
Supplement 5 Manufacturing (CMC) Approved June 7, 1999 —
Supplement 4 Manufacturing (CMC) Approved November 19, 1998 —
Supplement 3 Manufacturing (CMC) Approved March 13, 1998 —
Supplement 1 Manufacturing (CMC) Approved June 28, 1995 —
Supplement 2 Manufacturing (CMC) Approved May 9, 1995 —
Original application 1 Approved December 28, 1994 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20240620). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20240620 HUMAN PRESCRIPTION DRUG · 20220801 HUMAN PRESCRIPTION DRUG · 20201024

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Sulfacetamide Sodium Ophthalmic Solution, USP 10% is indicated for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms, and as an adjunctive in systemic sulfonamide therapy of trachoma: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. Topically applied sulfonamides do not provide adequate coverage against Neisseria species, Serratia marcescens and Pseudomonas aeruginosa . A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION For conjunctivitis and other superficial ocular infections: Instill one or two drops into the conjunctival sac(s) of the affected eye(s) every two to three hours initially. Dosages may be tapered by increasing the time interval between doses as the condition responds. The usual duration of treatment is seven to ten days. For trachoma: Instill two drops into the conjunctival sac(s) of the affected eye(s) every two hours. Topical administration must be accompanied by systemic administration.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Sulfacetamide Sodium Ophthalmic Solution, USP 10% is contraindicated in individuals who have a hypersensitivity to sulfonamides or to any ingredient of the preparation.

WARNINGS FOR TOPICAL EYE USE ONLY - NOT FOR INJECTION. FATALITIES HAVE OCCURRED, ALTHOUGH RARELY, DUE TO SEVERE REACTIONS TO SULFONAMIDES INCLUDING STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, FULMINANT HEPATIC NECROSIS, AGRANULOCYTOSIS, APLASTIC ANEMIA AND OTHER BLOOD DYSCRASIAS. Sensitizations may recur when a sulfonamide is readministered, irrespective of the route of administration. Sensitivity reactions have been reported in individuals with no prior history of sulfonamide hypersensitivity. At the first sign of hypersensitivity, skin rash or other serious reaction, discontinue use of this preparation.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS Bacterial and fungal corneal ulcers have developed during treatment with sulfonamide ophthalmic preparations. The most frequently reported reactions are local irritation, stinging and burning. Less commonly reported reactions include non-specific conjunctivitis, conjunctival hyperemia, secondary infections and allergic reactions. Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias (see WARNINGS ). To report SUSPECTED ADVERSE REACTIONS, contact Bausch + Lomb, a division of Valeant Pharmaceuticals North America LLC, at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Drug Interactions

openFDA Drug Labeling

Drug Interactions Sulfacetamide preparations are incompatible with silver preparations.

Description

openFDA Drug Labeling

DESCRIPTION Sulfacetamide Sodium Ophthalmic Solution, USP 10% is a sterile, topical antibacterial agent for ophthalmic use. The active ingredient is represented by the following structural formula: C 8 H 9 N 2 NaO 3 S • H 2 O Mol. Wt. 254.24 Chemical name: N -Sulfanilylacetamide monosodium salt monohydrate. Each mL contains: ACTIVE: Sulfacetamide Sodium, 100 mg/mL (10%); INACTIVES: Methylcellulose, Purified Water, Sodium Thiosulfate. Sodium Phosphate Monobasic may be added to adjust pH (6.8 - 8.0). PRESERVATIVES ADDED: Methylparaben 0.05% and Propylparaben 0.01%. The osmolality range is 700-1300 mOsm/kg. Sulfacetamide Sodium (structural formula)

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Sulfacetamide Sodium Ophthalmic Solution, USP 10% is supplied in a plastic squeeze bottle with a controlled drop tip in the following size: NDC 71205-689-15 15 mL bottle Storage: Store between 2° to 25°C (36° to 77°F). Sulfonamide solutions, on long standing, will darken in color and should be discarded. Keep out of reach of children. Distributed by: Bausch + Lomb, a division of Bausch Health US, LLC Bridgewater, NJ 08807 USA Manufactured by: Bausch & Lomb Incorporated Tampa, FL 33637 USA © 2020 Bausch & Lomb Incorporated or its affiliates Relabeled by: Proficient Rx LP Thousand Oaks, CA 91320 Revised: April 2020 do not use

Adverse event reports

Source: openFDA FAERS
601
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: SULFACETAMIDE SODIUM. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
50090-0246-0 50090-0246 A-S Medication Solutions 1 BOTTLE, DROPPER in 1 CARTON (50090-0246-0) / 15 mL in 1 BOTTLE, DROPPER June 29, 2016
76420-090-15 76420-090 Asclemed USA, Inc. 15 mL in 1 BOTTLE, DROPPER (76420-090-15) October 24, 2020
24208-670-04 24208-670 Bausch & Lomb Incorporated 1 BOTTLE, DROPPER in 1 CARTON (24208-670-04) / 15 mL in 1 BOTTLE, DROPPER December 28, 1994
68071-5123-5 68071-5123 NuCare Pharmaceuticals,Inc. 15 mL in 1 BOTTLE, DROPPER (68071-5123-5) December 6, 2019
68788-9871-1 68788-9871 Preferred Pharmaceuticals, Inc 15 mL in 1 BOTTLE, DROPPER (68788-9871-1) February 28, 2012
71205-689-15 71205-689 Proficient Rx LP 1 BOTTLE, DROPPER in 1 CARTON (71205-689-15) / 15 mL in 1 BOTTLE, DROPPER August 26, 2022
50090-0246 50090-0246 A-S Medication Solutions — December 28, 1994
76420-090 76420-090 Asclemed USA, Inc. — December 28, 1994
24208-670 24208-670 Bausch & Lomb Incorporated — December 28, 1994
68071-5123 68071-5123 NuCare Pharmaceuticals,Inc. — December 28, 1994
68788-9871 68788-9871 Preferred Pharmaceuticals, Inc — February 28, 2012
71205-689 71205-689 Proficient Rx LP — December 28, 1994

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 11 sections on this page.